Bicycle Therapeutics (BCYC) Shares Outstanding (Diluted Average) (2019 - 2026)

Bicycle Therapeutics (BCYC) has 8 years of Shares Outstanding (Diluted Average) data on file, last reported at $69.7 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 0.7% year-over-year to $69.7 million; the trailing twelve-month figure through Mar 2026 stood at $69.7 million (up 0.7% YoY), and the FY2025 full-year result was $69.3 million, up 19.02% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $69.7 million, up from $69.3 million in the prior quarter.
• Across five years, Shares Outstanding (Diluted Average) topped out at $69.7 million in Q1 2026 and bottomed at $29.6 million in Q1 2022.
• The 5-year median for Shares Outstanding (Diluted Average) is $42.6 million (2024), against an average of $47.7 million.
• The widest annual swing landed in 2024, when Shares Outstanding (Diluted Average) jumped 107.23%; it then climbed 0.38% in 2025.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $29.7 million in 2022, then climbed by 20.0% to $35.6 million in 2023, then surged by 63.54% to $58.2 million in 2024, then climbed by 19.02% to $69.3 million in 2025, then climbed by 0.58% to $69.7 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $69.7 million (Q1 2026), $69.3 million (Q4 2025), and $69.3 million (Q3 2025), per Business Quant data.

Peer Comparison